Novartis Heart-Failure Drug Wins 'Breakthrough' Status at FDA Businessweek Novartis AG (NOVN) won “breakthrough” status from U.S. regulators for an experimental drug to treat acute heart failure, raising the prospect of faster approval. Serelaxin, a man-made version of a hormone found in pregnant women, reduced death rates by ... |
